Optimizing MATRix as remission induction in PCNSL: de-escalated induction treatment in newly diagnosed primary CNS lymphoma

Optimizing MATRix as remission induction in PCNSL: de-escalated induction treatment in newly diagnosed primary CNS lymphoma

Abstract Background Primary diffuse large B-cell lymphoma (DLBCL) of the central nervous system (PCNSL) is a rare disorder with an increasing incidence over the past decades. High-level evidence has been reported for the MATRix regimen (high-dose methotrexate (HD-MTX), high-dose AraC (HD-AraC), thio...

Full description

Bibliographic Details
Main Authors: Julia Wendler, Christopher P. Fox, Elke Valk, Cora Steinheber, Heidi Fricker, Lisa K. Isbell, Simone Neumaier, Jessica Okosun, Florian Scherer, Gabriele Ihorst, Kate Cwynarski, Elisabeth Schorb, Gerald Illerhaus
Format: Article
Language:English
Published: BMC 2022-09-01
Series:BMC Cancer
Subjects:
Primary central nervous system lymphoma (PCNSL)
High-dose chemotherapy (HCT)
Autologous stem cell transplantation (ASCT)
Toxicity
De-escalation
Online Access:https://doi.org/10.1186/s12885-022-09723-w

Internet

https://doi.org/10.1186/s12885-022-09723-w

Similar Items